- Home
- WBX vs VNDA Comparison
WBX vs VNDA Comparison
Compare WBX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- VNDA
- Stock Information
- Founded
- WBX 2015
- VNDA 2002
- Country
- WBX Spain
- VNDA United States
- Employees
- WBX N/A
- VNDA N/A
- Industry
- WBX Industrial Specialties
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- VNDA Health Care
- Exchange
- WBX Nasdaq
- VNDA Nasdaq
- Market Cap
- WBX 66.9M
- VNDA 249.4M
- IPO Year
- WBX N/A
- VNDA 2006
- Fundamental
- Price
- WBX $4.11
- VNDA $4.43
- Analyst Decision
- WBX Buy
- VNDA Strong Buy
- Analyst Count
- WBX 4
- VNDA 2
- Target Price
- WBX $10.50
- VNDA $16.50
- AVG Volume (30 Days)
- WBX 17.9K
- VNDA 352.3K
- Earning Date
- WBX 11-05-2025
- VNDA 11-05-2025
- Dividend Yield
- WBX N/A
- VNDA N/A
- EPS Growth
- WBX N/A
- VNDA N/A
- EPS
- WBX N/A
- VNDA N/A
- Revenue
- WBX $173,788,608.00
- VNDA $203,467,000.00
- Revenue This Year
- WBX N/A
- VNDA $15.45
- Revenue Next Year
- WBX $46.25
- VNDA $37.82
- P/E Ratio
- WBX N/A
- VNDA N/A
- Revenue Growth
- WBX N/A
- VNDA 11.78
- 52 Week Low
- WBX $3.69
- VNDA $3.81
- 52 Week High
- WBX $26.20
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- WBX 47.24
- VNDA 44.27
- Support Level
- WBX $3.94
- VNDA $4.36
- Resistance Level
- WBX $4.20
- VNDA $4.64
- Average True Range (ATR)
- WBX 0.20
- VNDA 0.16
- MACD
- WBX 0.02
- VNDA -0.02
- Stochastic Oscillator
- WBX 70.00
- VNDA 12.71
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.